Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: NRM005
MIFTS: 60

Neuromuscular Disease

Categories: Nephrological diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Neuromuscular Disease

About this section

MalaCards integrated aliases for Neuromuscular Disease:

Name: Neuromuscular Disease 12 15
Neuromuscular Diseases 55 6 44 73
Neuromuscular Disorders 43

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:440
ICD10 33 G70.9 N31.9
ICD9CM 35 358 358.9
MeSH 44 D009468
UMLS 73 C0027868
Sources

Summaries for Neuromuscular Disease

About this section
MedlinePlus : 43 Neuromuscular disorders affect the nerves that control your voluntary muscles. Voluntary muscles are the ones you can control, like in your arms and legs. Your nerve cells, also called neurons, send the messages that control these muscles. When the neurons become unhealthy or die, communication between your nervous system and muscles breaks down. As a result, your muscles weaken and waste away. The weakness can lead to twitching, cramps, aches and pains, and joint and movement problems. Sometimes it also affects heart function and your ability to breathe. Examples of neuromuscular disorders include Amyotrophic lateral sclerosis Multiple sclerosis Myasthenia gravis Spinal muscular atrophy Many neuromuscular diseases are genetic, which means they run in families or there is a mutation in your genes. Sometimes, an immune system disorder can cause them. Most of them have no cure. The goal of treatment is to improve symptoms, increase mobility and lengthen life.

MalaCards based summary : Neuromuscular Disease, also known as neuromuscular diseases, is related to central core disease of muscle and spinal muscular atrophy, type ii, and has symptoms including athetosis, back pain and headache. An important gene associated with Neuromuscular Disease is TRPV4 (Transient Receptor Potential Cation Channel Subfamily V Member 4), and among its related pathways/superpathways are Cardiac conduction and Agrin Interactions at Neuromuscular Junction. The drugs Zinc and Naproxen have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, testes and brain, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A neuropathy that affect the nerves that control the voluntary muscles.

Wikipedia : 76 Neuromuscular disease is a very broad term that encompasses many diseases and ailments that impair the... more...

Sources

Related Diseases for Neuromuscular Disease

About this section

Diseases related to Neuromuscular Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 141)
# Related Disease Score Top Affiliating Genes
1 central core disease of muscle 33.4 DES GAA RYR1
2 spinal muscular atrophy, type ii 32.7 SMN1 SMN2
3 foot drop 31.1 MPZ PMP22
4 respiratory failure 30.7 DCTN1 GAA LAMA2
5 charcot-marie-tooth disease 30.6 DCTN1 HSPB8 MPZ MTM1 PMP22 TRPV4
6 myopathy, congenital 30.3 DMD MTM1 RYR1
7 centronuclear myopathy 30.3 DMD MTM1 RYR1
8 muscular atrophy 30.2 SMN1 SMN2 TRPV4
9 muscular dystrophy, becker type 30.2 DMD LAMA2 UTRN
10 myotonia 29.9 DMD DMPK SCN4A
11 malignant hyperthermia 29.8 DMD LAMA2 RYR1 SCN4A
12 peripheral nervous system disease 29.5 MPZ MUSK PMP22 SMN1 SMN2
13 muscular dystrophy 29.1 DES DMD DMPK GNE LAMA2 PABPN1
14 myopathy 26.5 DES DMD DMPK GAA GNE LAMA2
15 ophthalmoplegic neuromuscular disorder with abnormal mitochondria 12.0
16 lateral sclerosis 11.2
17 myasthenia gravis 11.2
18 emery-dreifuss muscular dystrophy 1, x-linked 11.1
19 spinal muscular atrophy, type i 11.1
20 kearns-sayre syndrome 11.1
21 extracardiac rhabdomyoma 11.0 DES DMD
22 cardioneuromyopathy with hyaline masses and nemaline rods 11.0 DES DMD
23 spinal muscular atrophy 11.0
24 microcolon 11.0 DES DMD
25 hereditary neuropathy with liability to pressure palsy 10.9 MPZ PMP22
26 congenital hypomyelination neuropathy 10.9 MPZ PMP22
27 charcot-marie-tooth neuropathy type 1 10.9 MPZ PMP22
28 roussy-levy hereditary areflexic dystasia 10.9 MPZ PMP22
29 charcot-marie-tooth disease, demyelinating, type 1f 10.9 MPZ PMP22
30 cytoplasmic body myopathy 10.9 DES DMD UTRN
31 charcot-marie-tooth disease, demyelinating, type 1c 10.8 MPZ PMP22
32 juvenile spinal muscular atrophy 10.8 SMN1 SMN2
33 charcot-marie-tooth disease, dominant intermediate b 10.8 MTM1 RYR1
34 reducing body myopathy 10.8 DES DMD
35 oculopharyngodistal myopathy 10.8 GNE PABPN1
36 spinal muscular atrophy, type iv 10.8 SMN1 SMN2
37 survival motor neuron spinal muscular atrophy 10.7 SMN1 SMN2
38 isolated hyperckemia 10.7 DMD LAMA2
39 proximal spinal muscular atrophy 10.7 DES SMN1 SMN2
40 spinal muscular atrophy, type iii 10.7 SMN1 SMN2
41 cardiomyopathy, dilated, 1b 10.7 DMD LAMA2
42 spinal disease 10.7 SMN1 SMN2
43 progressive muscular atrophy 10.6 SMN1 SMN2 TRPV4
44 oculopharyngeal muscular dystrophy 10.6
45 mitochondrial myopathy 10.6
46 native american myopathy 10.6
47 neuronopathy, distal hereditary motor, type va 10.6
48 brody myopathy 10.6
49 amyotrophy, monomelic 10.6
50 neuronopathy, distal hereditary motor, type vb 10.6

Comorbidity relations with Neuromuscular Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Heart Disease
Swallowing Disorders

Graphical network of the top 20 diseases related to Neuromuscular Disease:



Diseases related to Neuromuscular Disease
Sources

Symptoms & Phenotypes for Neuromuscular Disease

About this section

UMLS symptoms related to Neuromuscular Disease:


athetosis, back pain, headache, muscle cramp, muscle spasticity, myoclonus, pain, sciatica, seizures, syncope, torticollis, tremor, chronic pain, vertigo/dizziness, sleeplessness

MGI Mouse Phenotypes related to Neuromuscular Disease:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 UTRN TRPV4 DMD LAMA2 MPZ GAA
2 homeostasis/metabolism MP:0005376 10.35 UTRN SYNC TRPV4 HSPB8 DMD LAMA2
3 cellular MP:0005384 10.27 DES HSPB8 DMD LAMA2 GAA DCTN1
4 cardiovascular system MP:0005385 10.26 UTRN SYNC TRPV4 HSPB8 DMD DMPK
5 growth/size/body region MP:0005378 10.17 UTRN SMN2 GNE DMD LAMA2 GAA
6 mortality/aging MP:0010768 10.13 UTRN DES HSPB8 DMD LAMA2 MPZ
7 muscle MP:0005369 10.09 UTRN SYNC TRPV4 HSPB8 DMD LAMA2
8 hearing/vestibular/ear MP:0005377 9.88 TRPV4 SMN2 DMD LAMA2 SCN4A PMP22
9 limbs/digits/tail MP:0005371 9.8 UTRN SMN2 DMD DCTN1 RYR1 PMP22
10 respiratory system MP:0005388 9.61 UTRN TRPV4 HSPB8 DMD MUSK SCN4A
11 skeleton MP:0005390 9.28 UTRN DMD LAMA2 GAA DCTN1 MUSK
Sources

Drugs & Therapeutics for Neuromuscular Disease

About this section

Drugs for Neuromuscular Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 940)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6 23994
2
Naproxen Approved, Vet_approved Phase 4,Phase 2 22204-53-1 1302 156391
3
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
4
Menthol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 2216-51-5 16666
5
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
6
Riluzole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1744-22-5 5070
7
Abatacept Approved Phase 4,Phase 3,Phase 2,Early Phase 1 332348-12-6 10237
8
Imipramine Approved Phase 4 50-49-7 3696
9
Ramipril Approved Phase 4 87333-19-5 5362129
10
Etoricoxib Approved, Investigational Phase 4,Phase 2,Phase 1 202409-33-4 123619
11
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2180-92-9, 38396-39-3 2474
12
Iron Approved Phase 4,Phase 3,Phase 2,Not Applicable 7439-89-6 23925
13
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
14
Hydroxocobalamin Approved Phase 4,Phase 3,Phase 2,Not Applicable 13422-51-0 11953898 44475014
15
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 2 10118-90-8 5281021
16
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
17
Methotrexate Approved Phase 4,Phase 3,Phase 2 1959-05-2, 59-05-2 126941
18
Tramadol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 27203-92-5 33741
19
Norepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-41-2 439260
20
Carbamazepine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 298-46-4 2554
21
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 15307-86-5 3033
22
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 6740-88-1 3821
23
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 60142-96-3 3446
24
Amitriptyline Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-48-6 2160
25
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 57-27-2 5288826
26
Capsaicin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 404-86-4 1548943
27
Pirfenidone Approved, Investigational Phase 4,Phase 2,Phase 1 53179-13-8 40632
28
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
30
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 124-94-7 31307
31
Naloxone Approved, Vet_approved Phase 4,Phase 2 465-65-6 5284596
32
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 76-42-6 5284603
33
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
34
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
35
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
36
Citalopram Approved Phase 4,Phase 3,Not Applicable 59729-33-8 2771
37
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
38
Milnacipran Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 92623-85-3 65833
39
Perphenazine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 58-39-9 4748
40
Nabilone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51022-71-0 5284592
41
Azathioprine Approved Phase 4,Phase 3,Not Applicable 446-86-6 2265
42
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
43
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1994-09-7, 94-09-7 2337
44
Oxcarbazepine Approved Phase 4,Not Applicable 28721-07-5 34312
45
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
46
Epinephrine Approved, Vet_approved Phase 4,Not Applicable 51-43-4 5816
47
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
48
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 1972-08-3 16078
49
Sodium oxybate Approved Phase 4,Phase 3,Phase 2 502-85-2 5360545
50
Cyclobenzaprine Approved Phase 4,Phase 3,Phase 2,Not Applicable 303-53-7 2895

Interventional clinical trials:

(show top 50) (show all 4332)
# Name Status NCT ID Phase Drugs
1 Comparison of Pressure Support and Pressure Control Ventilation in Chronic Respiratory Failure Unknown status NCT00994552 Phase 4
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Comparative Study of Non-Invasive Mask Ventilation vs Cuirass Ventilation in Patients With Acute Respiratory Failure. Unknown status NCT00331656 Phase 4
4 A Post-marketing Evaluation of a Compound Traditional Chinese Herbal Medicine, Qishe Pill, on Cervical Radiculopathy Unknown status NCT01875562 Phase 4 Qishe Pill
5 Imipramine and Pregabalin Combination in Painful Polyneuropathy Unknown status NCT01047488 Phase 4 Imipramine;Pregabalin;Imipramine, pregabalin;Placebo
6 The Impact of Perioperative Gabapentin on Chronic Groin Pain After Inguinal Hernia Repair Unknown status NCT02419443 Phase 4 Gabapentin;Placebo
7 Bi-Axial Rotating Magnetic Field Therapy in Refractory Neuropathic Foot Pain Secondary to Diabetic Peripheral Neuropathy Unknown status NCT00123136 Phase 4
8 Study of Fibromyalgia Treated With Milnacipran Unknown status NCT01125423 Phase 4 Milnacipran
9 Study Assessing the Efficacy of Etoricoxib in Female Patients With Fibromyalgia Unknown status NCT00755521 Phase 4 etoricoxib
10 Determination of the Antidepressant Duloxetine in Plasma to Improve the Knowledge of the Analgesic Action of Antidepressants on Chronic Neuropathic Pain Unknown status NCT02846701 Phase 4 duloxetine
11 Evaluation of the Efficacy, Tolerability and Safety of Etoricoxib (Arcoxia) in Patients With Neuropathic Pain Unknown status NCT01264237 Phase 4 Etoricoxib;Placebo
12 Cyclobenzaprine Extended Release (ER) for Fibromyalgia Unknown status NCT01041495 Phase 4 cyclobenzaprine ER (AMRIX);placebo
13 Conservative Versus Aggressive Discectomy for Primary Disc Herniation With Radiculopathy Unknown status NCT01204008 Phase 4
14 Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Unknown status NCT02033057 Phase 4
15 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
16 Comparison of Intravenous Ibuprofen and Paracetamol in Patients With Sciatica Presented to the Emergency Department Unknown status NCT02777320 Phase 4 paracetamol;Ibuprofen
17 IV Paracetamol vs IV Morphine vs Placebo in Sciatalgia Unknown status NCT02504996 Phase 4 Paracetamol;morphine;Placebo
18 Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain Unknown status NCT02339662 Phase 4 Gabapentin;Amitriptyline
19 Preventing Pain After Heart Surgery Unknown status NCT01480765 Phase 4 Pregabalin;Ketamine infusion;Placebo capsules;Placebo infusion
20 Ramipril Versus Carvedilol in Duchenne and Becker Patients Unknown status NCT00819845 Phase 4 carvedilol;ramipril
21 Qutenza for Critical Ischaemia in End Stage Renal Failure Unknown status NCT01704339 Phase 4 QUTENZA
22 Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine Unknown status NCT01841671 Phase 4
23 A Phase IV Trial of Neuroprotection With ACTH in Acute Optic Neuritis Unknown status NCT01838174 Phase 4 ACTHAR Gel (ACTH);IV steroids with oral taper
24 Non-Invasive Ventilation in Amyotrophic Lateral Sclerosis Unknown status NCT00560287 Phase 4
25 Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy Unknown status NCT01770964 Phase 4 Pregabalin;placebo
26 Sodium Oxybate in Patients With Chronic Fatigue Syndrome. Unknown status NCT01584934 Phase 4 Sodium oxybate;Placebo
27 Pregabalin for the Treatment and Prevention of Spinal Cord Injury Neuropathic Pain Unknown status NCT01479556 Phase 4 Pregabalin;Placebo
28 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
29 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
30 The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy Unknown status NCT00606775 Phase 4 Carvedilol
31 Effects of Pregabalin on Mechanical Hyperalgesia Unknown status NCT00310583 Phase 4 Pregabalin
32 Inspiratory Muscle Training in Patients With Autonomic Neuropathic Unknown status NCT00752440 Phase 4
33 Ambulatory Adaptation to Non-Invasive Mechanical Ventilation Completed NCT00698958 Phase 4
34 Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients Completed NCT00299650 Phase 4 cisatracurium;Placebo;Cisatracurium besilate
35 Comparison of the Analgesic Effect of Different Local Anesthetics in Interscalene Nerve Block for Shoulder Surgery Completed NCT02691442 Phase 4 Ropivacaine 0.75%;Levobupivacaine 0.5%;Levobupivacaine 0.5% + epinephrin 1/200000
36 The Effect of α-lipoic Acid Treatment in Patient With Cardiac Autonomic Neuropathy Completed NCT02056366 Phase 4 α-lipoic acid
37 A Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Chemotherapy-Induced Peripheral Neuropathy (CIPN) Completed NCT01675531 Phase 4 Targin
38 Intrathecal Bolus Doses of Ziconotide Completed NCT01373983 Phase 4 Ziconotide
39 Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109) Completed NCT01192113 Phase 4 Mecobalamin IV Injection;Mecobalamin IM injection;Mecobalamin IV or IM injection
40 Evaluation of the Efficacy of Cesametâ„¢ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy Completed NCT00380965 Phase 4 Cesametâ„¢ (nabilone)
41 Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations Completed NCT02260388 Phase 4 Nortriptyline;Duloxetine;Pregabalin;Mexiletine
42 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
43 Differences in Atorvastatin Metabolite Ratios as a Diagnostic Tool in Detecting Atorvastatin Induced Myotoxicity Completed NCT00199745 Phase 4 atorvastatin
44 Escitalopram as a Treatment for Pain in Polyneuropathy Completed NCT00162968 Phase 4 escitalopram
45 Arthroplasty Versus Fusion in Anterior Cervical Surgery: Prospective Study of the Impact on the Adjacent Level Completed NCT00554528 Phase 4
46 Prophylactic Administration of Vitamin C in Wrist Fractures Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
47 Study of Metanx® in Subjects With Type 2 Diabetic Peripheral Neuropathy (DPN) Completed NCT00726713 Phase 4
48 A Study to Compare Safety and Efficacy of Tramadol Hydrochloride/Acetaminophen With Gabapentin in Participants With Diabetic Neuropathy Completed NCT00634543 Phase 4 Tramadol hydrochloride/ Acetaminophen;Gabapentin
49 Effect of Pulsing Electrical Fields on Lower Extremity Diabetic Neuropathy: A Pilot, Open-Label Study Completed NCT00614341 Phase 4
50 A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy Completed NCT00573261 Phase 4 Pregabalin;Placebo

Search NIH Clinical Center for Neuromuscular Disease

Cochrane evidence based reviews: neuromuscular diseases

Sources

Genetic Tests for Neuromuscular Disease

About this section
Sources

Anatomical Context for Neuromuscular Disease

About this section

MalaCards organs/tissues related to Neuromuscular Disease:

41
Spinal Cord, Testes, Brain, Bone, Heart, Cortex, Skin
Sources

Publications for Neuromuscular Disease

About this section

Articles related to Neuromuscular Disease:

(show top 50) (show all 678)
# Title Authors Year
1
Breathing with neuromuscular disease: Does compensatory plasticity in the motor drive to breathe offer a potential therapeutic target in muscular dystrophy? ( 29933052 )
2018
2
Noninvasive Ventilation for Neuromuscular Disease. ( 29779601 )
2018
3
Swallowing and Secretion Management in Neuromuscular Disease. ( 29779602 )
2018
4
The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. ( 29479275 )
2018
5
Physical exercise in adults with hereditary neuromuscular disease. ( 29947206 )
2018
6
Swallowing impairments in Amyotrophic Lateral Sclerosis and Myotonic Dystrophy type 1: Looking for the portrait of dysphagic patient in neuromuscular diseases. ( 29400682 )
2018
7
Respiratory Diagnostic Tools in Neuromuscular Disease. ( 29914128 )
2018
8
Case of paediatric neuromuscular disease with a surprising clinical outcome: time to challenge the dogma? ( 29382800 )
2018
9
Neuromuscular disease-specific questionnaire to assess quality of life in patients with chronic inflammatory demyelinating polyradiculoneuropathy. ( 29360221 )
2018
10
Reflections on 50 Years of Neuroscience Nursing: Movement Disorders, Neuromuscular Disease, and Multiple Sclerosis. ( 29266080 )
2018
11
New Cav2 calcium channel gating modifiers with agonist activity and therapeutic potential to treat neuromuscular disease. ( 29246857 )
2018
12
The clinical usefulness of a self-administered questionnaire for sleep-disordered breathing in patients with neuromuscular disease. ( 29445539 )
2018
13
Use of Mechanical Insufflation-Exsufflation Devices for Airway Clearance in Subjects With Neuromuscular Disease. ( 28108686 )
2017
14
Stress Fracture of the Fifth Metatarsal in Foot Deformity Secondary to Neuromuscular Disease: Experiences of Deformity Correction Treatment-A Report of 3 Cases and Review of the Literature. ( 29172689 )
2017
15
The New Zealand Neuromuscular Disease Patient Registry; Five Years and a Thousand Patients. ( 28800337 )
2017
16
Noninvasive Respiratory Management of Patients With Neuromuscular Disease. ( 28971036 )
2017
17
Biallelic SCN10A mutations in neuromuscular disease and epileptic encephalopathy. ( 28078312 )
2017
18
A population-based epidemiologic study of adult neuromuscular disease in the Republic of Ireland. ( 27927941 )
2017
19
Respiratory Implications of Pediatric Neuromuscular Disease. ( 28546380 )
2017
20
MRC Centre Neuromuscular Biobank (Newcastle and London): Supporting and facilitating rare and neuromuscular disease research worldwide. ( 28864117 )
2017
21
The quality of life in genetic neuromuscular disease questionnaire: Rasch validation of the French version. ( 28164330 )
2017
22
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. ( 28379182 )
2017
23
Successful Extubation After Weaning Failure by Noninvasive Ventilation in Patients With Neuromuscular Disease: Case Series. ( 28758083 )
2017
24
Imaging in Neuromuscular Disease 2017: First International Conference on Imaging in Neuromuscular Disease, 19th - 21st November 2017, Berlin, Germany. ( 29103047 )
2017
25
Neuromuscular Disease: Cardiac Manifestations and Sudden Death Risk. ( 29173414 )
2017
26
Are mice good models for human neuromuscular disease? Comparing muscle excursions in walking between mice and humans. ( 29145886 )
2017
27
Cardiac Manifestations of Neuromuscular Disease. ( 28601412 )
2017
28
Letter to the Editor: Successful Extubation After Weaning Failure by Noninvasive Ventilation in Patients With Neuromuscular Disease - Do We Appreciate the Bigger Picture? ( 29201832 )
2017
29
Imaging of respiratory muscles in neuromuscular disease: A review. ( 29398294 )
2017
30
Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease. ( 28448001 )
2017
31
Natural History, Trial Readiness and Gene Discovery: Advances in Patient Registries for Neuromuscular Disease. ( 29214567 )
2017
32
Respiratory complications, management and treatments for neuromuscular disease in children. ( 28338488 )
2017
33
Sleep-disordered breathing in patients with neuromuscular disease. ( 28702830 )
2017
34
Neuromuscular disease: Tadalafil fails to halt the progression of Duchenne muscular dystrophy. ( 29064468 )
2017
35
Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease. ( 28178525 )
2017
36
The new neuromuscular disease related with defects in the ASC-1 complex: report of a second case confirms ASCC1 involvement. ( 28218388 )
2017
37
Sleep-Disordered Breathing in Neuromuscular Disease: Diagnostic and Therapeutic Challenges. ( 28372949 )
2017
38
Invasive versus non-invasive ventilation for acute respiratory failure in neuromuscular disease and chest wall disorders. ( 29199768 )
2017
39
Stability and relative validity of the Neuromuscular Disease Impact Profile (NMDIP). ( 28490360 )
2017
40
Registry Participation in Neuromuscular Disease. ( 27922505 )
2016
41
Neuromuscular disease: Mitochondrial dysfunction could precipitate motor neuron loss in spinal muscular atrophy. ( 27562548 )
2016
42
Neuromuscular disease. Diagnosis and discovery in limb-girdle muscular dystrophy. ( 26670295 )
2016
43
Variant U1 snRNAs are implicated in human pluripotent stem cell maintenance and neuromuscular disease. ( 27536002 )
2016
44
Medical School Hotline: Medical Student Insights on Pediatric Neuromuscular Disease in Hawai'i. ( 27099807 )
2016
45
One clinic's experience with carbon fiber orthoses in neuromuscular disease. ( 27356926 )
2016
46
Relationship between disability and life satisfaction in adult patients with neuromuscular disease. ( 27677022 )
2016
47
Same-day physical therapy consults in an outpatient neuromuscular disease physician clinic. ( 27757040 )
2016
48
Neuromuscular disease: Methotrexate has no steroid-sparing effect in patients with generalized myasthenia gravis. ( 27364745 )
2016
49
Response to Noninvasive Pco2 Monitoring During Sleep for Patients with Neuromuscular Disease. ( 26745219 )
2016
50
The utility of genetic testing in neuromuscular disease: A Consensus Statement From the AANEM on the Clinical Utility of Genetic Testing in Diagnosis of Neuromuscular Disease. ( 27554703 )
2016